This suggests that the classical KRAS-PI3K-AKT pathway is not essential for acquired resistance to sotorasib, whereas KRAS-independent PI3K activation favors such resistance in lung cancer cells [200]. This evidence concerns the gene KRAS and lung carcinoma.